This brand name is authorized in Austria, Estonia, Poland
The drug IODOPOL contains one active pharmaceutical ingredient (API):
|
1
Sodium iodide ¹³¹I
UNII 29VCO8ACHH - SODIUM IODIDE I-131
|
|
Iodide is actively transported by the sodium-iodide symporter (NIS) protein, in thyroid follicular cells. Sodium iodide ¹³¹I is used for the treatment of hyperthyroidism and selected cases of thyroid carcinoma. The beta emission of I 131 is responsible for the therapeutic effect. |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC code | Group title | Classification |
|---|---|---|
| V10XA01 | Sodium iodide (131I) | V Various → V10 Therapeutic radiopharmaceuticals → V10X Other therapeutic radiopharmaceuticals → V10XA Iodine (131I) compounds |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: EE | Ravimiamet | Identifier(s): 1749180 |
| Country: PL | Rejestru Produktów Leczniczych | Identifier(s): 100394007 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
